ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline (1) -…
stemadminBenefits Of Stem CellsNo comments

Galway, Ireland, and San Diego, USA, 17 December 2020 ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has secured three new exclusive option license agreements which strengthen its off-the-shelf, dual-targeted natural killer (NK) cell therapy platform and extend its pre-clinical pipeline to four programs across both hematological and solid tumors. The first option agreement, with Cellerant Therapeutics, gives exclusive rights to a humanized CLEC12A scFv binder. CLEC12A is strongly expressed by blasts in the majority of AML patients.

Read more
John Connolly has a new mission to tack on to his role at the Parker Institute: interim chief of a buzzy biotech backed by a pair of billionaires -…
stemadminBenefits Of Stem CellsNo comments

Five years after Gilead plunked down $725 million in cash to partner with Galapagos on filgotinib, new CEO Dan ODay has opted to shelve the rheumatoid arthritis program and all but a much smaller piece of the old development plan in the US. The big biotech said Tuesday afternoon that the FDA had erected a high barrier for this drug, which they couldnt see a way around or over

Read more
Cell Replacement Therapy A Promising Treatment for Age-Related Macular Degeneration – Technology Networks
stemadminBenefits Of Stem CellsNo comments

Lineage Cell Therapeuticsis a clinical-stage biotechnology company developing novel, off the shelf cell therapies for unmet medical needs. Lineages programs are based on its proprietary cell therapy platform and in-house development and manufacturing capabilities. Their lead program features the manufacture and transplant of retinal pigment epithelium cells for the treatment of dry age-related macular degeneration, one of the leading causes of blindness

Read more
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV – GlobeNewswire
stemadminBenefits Of Stem CellsNo comments

-Funding from the Bill & Melinda Gates Foundation will support research to enable CRISPR/Cas9-based therapies for HIV that can benefit patients worldwide- ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the receipt of a grant from the Bill & Melinda Gates Foundation to research in vivo gene editing therapies for the treatment of HIV.

Read more
Vascular therapies for mental health disorders – Open Access Government
stemadminBenefits Of Stem CellsNo comments

The global burden of mental health disorders and their consequences have been steadily increasing. It is currently known that an estimate of one in four people worldwide are affected by a form of mental illness. The World Health Organization has estimated that over 300 million people suffer from depression at a global level, 23 million with schizophrenia and 60 million with bipolar affective disorders.

Read more
Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition | DNA RNA and Cells | News…
stemadminBenefits Of Stem CellsNo comments

DetailsCategory: DNA RNA and CellsPublished on Tuesday, 08 December 2020 11:39Hits: 422 Initial data demonstrate early signs of safety, tolerability and robust immune responses in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic hematopoietic cell transplantation (allo-HSCT) GAITHERSBURG, MD, USA I December 07, 2020 I NexImmune, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the bodys own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced that City of Hopes Monzr Al Malki, M.D., delivered an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition featuring initial data from the Phase 1/2 trial of NEXI-001 in AML. Entitled Preliminary Results of the First-in-Human Study of NEXI-001, a Multi-Antigen Specific CD8+ T Cell Product, in Acute Myeloid Leukemia (AML) Patients with Relapsed Disease after Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Demonstrate Early Signs of Safety, Tolerability and Robust Immune Responses, the presentation included responses following a single infusion of the experimental therapy. These data represent safety and tolerability results from the first five patients treated and reflect a median of four months of follow-up with infusion doses ranging from 50-200 million total T cells.

Read more
City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference – Business Wire
stemadminBenefits Of Stem CellsNo comments

DUARTE, Calif.--(BUSINESS WIRE)--City of Hope doctors participated in research presented at the American Society of Hematology (ASH) virtual meeting, Dec. 5 to 8, that are helping advance the treatment of blood cancers, including one study which demonstrated allogeneic stem cell transplants do have a survival benefit for older adults with myelodysplastic syndromes (MDS) compared with current standard of care. The study is the largest and most definitive trial to demonstrate the benefits of an allogeneic stem cell transplantation for older adults with MDS, and is just one of numerous studies that City of Hope doctors help lead with the aim of finding more effective treatments of various blood cancers

Read more

Theme: Illdy.